AMPHOTERICIN-B LIPID COMPLEX TO TREAT INVASIVE FUNGAL-INFECTIONS IN CANCER-PATIENTS - REPORT OF EFFICACY AND SAFETY IN 20 PATIENTS

被引：18

作者：

ORAVCOVA, E

MISTRIK, M

SAKALOVA, A

DRGONA, L

KOLLAR, T

HELPIANSKA, L

ILAVSKA, I

SORKOVSKA, D

SPANIK, S

KUKUCKOVA, E

KRCMERY, V

机构：

[1] UNIV TRNAVA,DEPT CLIN MED,BRATISLAVA,SLOVAKIA

[2] COMENIUS UNIV BRATISLAVA,POSTGRAD MED SCH,DEPT CHEMOTHERAPY,BRATISLAVA,SLOVAKIA

[3] COMENIUS UNIV BRATISLAVA,SCH MED,NATL CANC CTR,DEPT MED,BRATISLAVA,SLOVAKIA

[4] COMENIUS UNIV BRATISLAVA,SCH MED,NATL CANC CTR,DEPT HEMATOL,BRATISLAVA,SLOVAKIA

[5] COMENIUS UNIV BRATISLAVA,SCH MED,DEPT ONCOL,BRATISLAVA,SLOVAKIA

来源：

CHEMOTHERAPY | 1995年 / 41卷 / 06期

关键词：

AMPHOTERICIN B LIPID COMPLEX; INFECTION; FUNGAL;

D O I：

10.1159/000239385

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

20 patients with proven or suspected fungal infections were treated with the amphotericin B lipid complex (ABLC) with a daily dose of 5 mg/kg for 1-25 days. 6 patients died during the therapy due to fungal infection (3) or underlying disease (3). One patient was not evaluable. 13 patients were cured and improved. ABLC was administered in patients with renal disese avoiding the use of conventional amphotericin B (AmB) because of nephrotoxicity or after failure with AmB. Except for hypokalemia persisting after AmB in 5 patients, no systemic adverse reaction appeared. ABLC is a promising, well-tolerated and effective drug for the therapy of fungal infections after the failure of a previous antifungal therapy or after toxic reactions due to AmB.

引用

页码：473 / 476

页数：4

共 50 条

[41] SAFETY AND EFFICACY OF ITRACONAZOLE IN PREVENTION OF FUNGAL-INFECTIONS IN NEUTROPENIC PATIENTS
THUNNISSEN, PLM
SIZOO, W
HENDRIKS, WDH
NETHERLANDS JOURNAL OF MEDICINE, 1991, 39 (1-2): : 84 - 91
[42] REDUCTION OF SYSTEMIC FUNGAL-INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES, NEUTROPENIA, AND PROLONGED FEVER BY EARLY AMPHOTERICIN-B THERAPY
ZIMMERMANNHOSLI, MB
STAHEL, RA
VOGT, P
OELZ, O
KLINISCHE WOCHENSCHRIFT, 1988, 66 (20): : 1010 - 1014
[43] A RANDOMIZED STUDY TO COMPARE ORAL FLUCONAZOLE TO AMPHOTERICIN-B IN THE PREVENTION OF FUNGAL-INFECTIONS IN PATIENTS WITH ACUTE-LEUKEMIA
ROZENBERGARSKA, M
DEKKER, AW
BRANGER, J
VERHOEF, J
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 (03) : 369 - 376
[44] LIPOSOMAL AMPHOTERICIN-B IN THE TREATMENT OF FUNGAL-INFECTIONS IN NEUTROPENIC PATIENTS - A SINGLE-CENTER EXPERIENCE OF 133 EPISODES IN 116 PATIENTS
MILLS, W
CHOPRA, R
LINCH, DC
GOLDSTONE, AH
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (04) : 754 - 760
[45] Efficacy and safety of Amphotericin B Lipid Complex Injection (ABLC) in solid-organ transplant recipients with invasive fungal infections
Linden, P
Williams, P
Chan, KM
CLINICAL TRANSPLANTATION, 2000, 14 (04) : 329 - 339
[46] PHARMACOKINETICS AND TOXICITY OF CONTINUOUS INFUSION AMPHOTERICIN-B IN CANCER-PATIENTS
CHABOT, GG
PAZDUR, R
VALERIOTE, FA
BAKER, LH
JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (04) : 307 - 310
[47] PROPHYLAXIS OF FUNGAL-INFECTIONS WITH KETOCONAZOLE IN CANCER-PATIENTS RECEIVING CYTOSTATIC THERAPY
KONIG, HJ
GEORGIOU, A
KRAFT, P
MAYER, U
MYCOSES, 1988, 31 (06) : 324 - 329
[48] PREVENTION OF BACTERIAL AND FUNGAL-INFECTIONS IN ACUTE-LEUKEMIA PATIENTS - A NEW AND POTENT COMBINATION OF ORAL NORFLOXACIN AND AMPHOTERICIN-B
YAMADA, T
DAN, K
NOMURA, T
INTERNAL MEDICINE, 1993, 32 (09) : 710 - 715
[49] Amphotericin B lipid complex (ABLC) for fungal infections in immunocompromised patients with hematologic malignancies
Mehta, J
Kelsey, SM
Chu, P
Powles, R
Singhal, S
Hazel, D
Newland, AC
Treleaven, J
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1000 - 1000
[50] TISSUE CONCENTRATIONS AND BIOACTIVITY OF AMPHOTERICIN-B IN CANCER-PATIENTS TREATED WITH AMPHOTERICIN-B-DEOXYCHOLATE
COLLETTE, N
VANDERAUWERA, P
LOPEZ, AP
HEYMANS, C
MEUNIER, F
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (03) : 362 - 368

← 1 2 3 4 5 →